Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Diabetes and Vascular Disease Research
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Green, B. D
Right arrow Articles by Bailey, C. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Green, B. D
Right arrow Articles by Bailey, C. J
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes

Brian D Green

School of Biological Sciences, Queens University Belfast, Belfast, BT9 5AG, UK

Peter R Flatt

School of Biomedical Sciences, University of Ulster, Coleraine, UK

Clifford J Bailey

School of Life and Health Sciences, Aston University, Birmingham, UK

Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPP IV prolongs and enhances the activity of endogenous GLP-1 and GIP, which serve as important prandial stimulators of insulin secretion and regulators of blood glucose control. In clinical trials DPP IV inhibitors (or ‘gliptins’) have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia.

Key Words: dipeptidyl peptidase IV • DPP IV • gliptin • incretin hormones • DPP IV inhibition.

Diabetes and Vascular Disease Research, Vol. 3, No. 3, 159-165 (2006)
DOI: 10.3132/dvdr.2006.024
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 The Diabetes EducatorHome page
R. K. Campbell and S. Miller
New Therapeutic Horizons: Mapping the Future of Glycemic Control With Incretin-based Therapy
The Diabetes Educator, September 1, 2009; 35(5): 731 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
O. B. Chaudhri, K. Wynne, and S. R. Bloom
Can Gut Hormones Control Appetite and Prevent Obesity?
Diabetes Care, February 1, 2008; 31(Supplement_2): S284 - S289.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
H. Chahal and T.A. Chowdhury
Gliptins: a new class of oral hypoglycaemic agent
QJM, November 1, 2007; 100(11): 671 - 677.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
Early and intensive treatment: glycaemic control in type 2 diabetes
Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 145 - 146.
[PDF]